ADH1A and Hypocalcemia: Further studies in larger groups of patients with various CASR mutations are needed to examine the effect of implementing our paradigm for the prevention of both hypocalcemia-related neurological symptoms and hypercalciuria with subsequent renal impairment in patients with ADH1.